{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T22:37:47Z","timestamp":1773268667360,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T00:00:00Z","timestamp":1773187200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"\n Objective<\/jats:title>\n \n The study aimed to establish a benefit-risk assessment (BRA) model utilizing multi-criteria decision analysis (MCDA), in order to evaluate the benefit-risk relationship of decoctions containing\n Aconitum carmichaeli Debx. (Fuzi)<\/jats:italic>\n in the treatment of rheumatoid arthritis (RA), laying the foundation for the decision-making on the use of clinical toxic botanical drugs and facilitating their rational application.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n The BRA framework of\n Fuzi<\/jats:italic>\n in the treatment of RA was evaluated through an intergrated approach combining Delphi survey, meta-analysis, MCDA modeling, and Bayesian Monte Carlo simulations. And also, the variations in benefits and risks when using\n Fuzi<\/jats:italic>\n under different conditions were simulated. The modeling of MCDA-BRA was employed various software tools, including Microsoft Office Excel 2016, Matlab R2014b, RevMan 5.4, Hiview 3, and Crystal Ball 11.1.2.4.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Based on the Delphi survey results involving 22 experts, a MCDA model for the BRA assessment of\n Fuzi<\/jats:italic>\n in RA treatment was constructed. The benefit criteria wighted at 49%, and encompassed secondary criteria such as the number of joints with pressure pain, the number of swollen joints, the duration of morning stiffness, and laboratory test markers. While risk criteria constituted 51% and included factors such as the incidence rate of adverse drug reactions\/events (ADRs\/ADEs) and damage to various bodily systems. After including 40 random clinical trials (RCTs) that used\n Fuzi<\/jats:italic>\n as a primary therapeutic agent in traditional Chinese medicines (TCM) decoction for RA, a meta-analysis was conducted. Combination of the meta-analysis results and BRA model, the BRA value of\n Fuzi<\/jats:italic>\n in the treatment of RA was ranging from 5 to 54, which means the benefit is superior to the risk of using\n Fuzi<\/jats:italic>\n for RA. RA patients with the pattern of cold and heat complex, 3\u201315\u00a0g dosage, lasting 2\u20133 months treatment course, and using decoction only, the risks borne by the patients were lower. Sensitivity analysis indicated stability of the evaluation outcomes.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusion<\/jats:title>\n \n The study, utilizing\n Fuzi<\/jats:italic>\n in the treatment of RA as an example, effectively explored the methodology of BRA for toxic botanical drugs. It simulated medication regimens that were more favorable to patients and established a solid foundation for risk management and the rational use of toxic TCM in clinical practice. However, interpretation of the findings should account for limitations in the underlying data.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3389\/fphar.2025.1505986","type":"journal-article","created":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:50:46Z","timestamp":1773211846000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Benefit-risk assessment of the use of toxic botanical drugs in superiority field: a case study on Aconitum carmichaeli Debx"],"prefix":"10.3389","volume":"16","author":[{"given":"Xiaomeng","family":"Zhang","sequence":"first","affiliation":[{"name":"Clinical Chinese Pharmacy Department, School of Chinese Materia Medica, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congcong","family":"Qu","sequence":"additional","affiliation":[{"name":"Clinical Chinese Pharmacy Department, School of Chinese Materia Medica, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Zhang","sequence":"additional","affiliation":[{"name":"Clinical Chinese Pharmacy Department, School of Chinese Materia Medica, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jintao","family":"Lyv","sequence":"additional","affiliation":[{"name":"Clinical Chinese Pharmacy Department, School of Chinese Materia Medica, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhijian","family":"Lin","sequence":"additional","affiliation":[{"name":"Clinical Chinese Pharmacy Department, School of Chinese Materia Medica, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinlong","family":"Liu","sequence":"additional","affiliation":[{"name":"Clinical Chinese Pharmacy Department, School of Chinese Materia Medica, Beijing University of Chinese Medicine","place":["Beijing, China"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2026,3,11]]},"reference":[{"key":"B1","first-page":"50","article-title":"Application of percentage weighting method in evaluating the quality of food hygiene work","author":"Ben","year":"2004","journal-title":"Jiangsu J. Prev. Med."},{"key":"B2","volume-title":"Report of the CHMP working group on benefit-risk assessment models and methods. (EMEA\/CHMP\/15404\/2007)","year":"2007"},{"key":"B3","first-page":"12","article-title":"Application effect of multi-criteria decision model on benefit and risk assessment of fexofenadine in the treatment of allergic rhinitis","volume":"23","author":"Guo","year":"2016","journal-title":"China Mod. Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"e155809","DOI":"10.1016\/j.cyto.2022.155809","article-title":"Aconiti lateralis radix praeparata lipid-soluble alkaloids alleviates IL-1\u03b2-induced inflammation of human fibroblast-like synoviocytes in rheumatoid arthritis by inhibiting NF-\u03baB and MAPKs signaling pathways and inducing apoptosis","volume":"151","author":"Guo","year":"2022","journal-title":"Cytokine"},{"key":"B5","first-page":"31","article-title":"Analysis of multi criteria decision analysis applied to the evaluation of medical insurance reimbursement projects at home and aboard","volume":"11","author":"He","year":"2016","journal-title":"China J. Pharm. Econ."},{"key":"B6","first-page":"323","article-title":"Study on the safety of fuzi compound in the treatment of patients with cold-dampness arthralgia syndrome","volume":"33","author":"Hou","year":"2014","journal-title":"Beijing J. Traditional Chin. Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"e0124806","DOI":"10.1371\/journal.pone.0124806","article-title":"Net clinical benefit of oral anticoagulants: a multiple criteria decision analysis","volume":"10","author":"Hsu","year":"2015","journal-title":"PloS One"},{"key":"B8","doi-asserted-by":"publisher","first-page":"3506","DOI":"10.3390\/ijms19113506","article-title":"Study on cardiotoxicity and mechanism of \u201cfuzi\u201d extracts based on metabonomics","volume":"19","author":"Huang","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B9","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1002\/pds.3958","article-title":"Recommendations for benefit-risk assessment methodologies and visual representations","volume":"25","author":"Hughes","year":"2016","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"B10","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1055\/s-0029-1240688","article-title":"Toxicity assessment of nine types of decoction pieces from the daughter root of Aconitum carmichaeli (fuzi) based on the chemical analysis of their diester diterpenoid alkaloids","volume":"76","author":"Lu","year":"2010","journal-title":"Planta Medica."},{"key":"B11","first-page":"473","article-title":"Overview of drug benefit-risk assessment research progress","volume":"10","author":"Lu","year":"2013","journal-title":"Chin. J. Pharmacovigil."},{"key":"B12","first-page":"499","article-title":"Based on the MCDA model, the benefit risk evaluation system of traditional Chinese medicine injection was constructed - taking shuanghuanglian injection in the treatment of acute upper respiratory tract infection as an example","volume":"26","author":"Lu","year":"2017","journal-title":"Chin. J. Pharmacovigil."},{"key":"B13","volume-title":"Ranking vaccines: a prioritization framework: phase I: demonstration of concept and a software blueprint","author":"Madhavan","year":"2012"},{"key":"B14","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s40273-019-00863-9","article-title":"Multi-criteria decision analysis software in healthcare priority setting:a systematic review","volume":"38","author":"Moreno","year":"2020","journal-title":"Pharmacoeconomics"},{"key":"B15","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1002\/pds.3636","article-title":"Balancing benefit and risk of medicines: a systematic review and classification of available methodologies","volume":"23","author":"Mt-Isa","year":"2014","journal-title":"Pharmacoepidemiol. Drug Safety"},{"key":"B16","volume-title":"Pharmacopoeia of the People's Republic of China (volume I)","year":"2020"},{"key":"B17","first-page":"253","article-title":"Establishment and implementation of post-marketing benefit-risk assessment strategy for traditional Chinese medicine","volume":"31","author":"Qiao","year":"2025","journal-title":"Chin. J. Exp. Traditional Med. Formulae"},{"key":"B18","doi-asserted-by":"publisher","first-page":"156","DOI":"10.24867\/IJIEM-2024-2-354","article-title":"Data normalization for root assessment methodology","volume":"15","author":"Trung","year":"2024","journal-title":"Int. J. Industrial Eng. Manag."},{"key":"B19","first-page":"210","article-title":"Combining DOE and EDAS methods for multi-criteria decision making","volume-title":"32nd international conference on organization and technology of maintenance (OTO 2023). OTO 2023. Lecture notes in networks and systems","author":"Trung","year":"2024"},{"key":"B20","doi-asserted-by":"publisher","first-page":"131","DOI":"10.18485\/aeletters.2023.8.3.5","article-title":"Enhancing handheld polishing machine selection: an integrated approach of marcos methods and weight determination techniques","volume":"8","author":"Truong","year":"2023","journal-title":"Appl. Eng. Lett."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1057\/jors.1994.175","article-title":"Decisions with multiple objectives: preferences and value tradeoffs","volume":"45","author":"Tsoukias","year":"1994","journal-title":"J. Oper. Res. Soc."},{"key":"B22","first-page":"92","article-title":"A study of data statistical processing method of Delphi method and its application","volume":"9","author":"Wang","year":"2011","journal-title":"J. Inn. Mong. Univ. Finance Econ."},{"key":"B23","first-page":"37","article-title":"Research progress on chemical composition analysis methods and pharmacological effects of aconite","volume":"22","author":"Wang","year":"2010","journal-title":"Strait Pharm. J."},{"key":"B24","first-page":"2688","article-title":"Chinese materia medica for warming interior: safety analysis and pharmacovigilance considerations","volume":"31","author":"Wang","year":"2016","journal-title":"China J. Traditional Chin. Med. Pharm."},{"key":"B25","volume-title":"Benefit-risk balance for marketed drugs: evaluating safety signals","year":"1998"},{"key":"B26","first-page":"752","article-title":"Method for risk assessment of drug benefit based on multi-criteria decision analysis model","volume":"14","author":"Xiong","year":"2017","journal-title":"Chin. J. Pharmacovigil."},{"key":"B27","volume-title":"Han dynasty, narrated. Wang shuhe (jin dynasty), collected. 1963. Synopsis of the golden chamber","author":"Zhang","year":"1963"},{"key":"B28","first-page":"127","article-title":"Benefit-risk assessment of Rocaxillin","volume":"10","author":"Zhou","year":"2013","journal-title":"Med. Innovation China"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1505986\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:50:50Z","timestamp":1773211850000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1505986\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,11]]},"references-count":28,"alternative-id":["10.3389\/fphar.2025.1505986"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1505986","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,11]]},"article-number":"1505986"}}